ART27.13

About Artelo Biosciences

Artelo Biosciences is a clinical-stage biotech focused on developing therapeutics that modulate lipid-signaling pathways, with a primary mission to improve treatments for cancer and related conditions. Its most advanced asset, ART27.13, has demonstrated promising Phase 2 efficacy in reversing weight loss and improving lean body mass in cancer anorexia-cachexia syndrome (CACS), positioning it as a potential first-in-class therapy. The company's strategy involves advancing this lead program while leveraging its platform to develop additional assets targeting the endocannabinoid system and fatty acid binding proteins. Artelo operates as a public, micro-cap company, navigating the high-risk, high-reward landscape of early-stage drug development.

Therapeutic Areas